Celebrating 25 years Est 1999-2024
*Across 3 years $2158.56 only $1079.28
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in...
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 27, 2024 – Genmab A/S (Nasdaq: GMAB). On...
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting...
Genmab Completes Acquisition of ProfoundBio Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 21, 2024 – Genmab A/S (Nasdaq: GMAB...
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 13, 2024 – Genmab A/S (Nasdaq: GMAB). On...
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; May 7, 2024 – Genmab A/S...
Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; May 6, 2024 – Genmab A/S (Nasdaq: GMAB). On...
Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full...
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq:...
Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.